

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the 2026 second extraordinary general meeting (the “EGM”) of AIM Vaccine Co., Ltd. (the “**Company**”) will be held at meeting room, 10/F, Gangwu Building, No. 1 Fenghe Road, Lujiazui Street, Pudong New District, Shanghai, the PRC at 2:00 p.m. on Monday, September 7, 2026 for the purpose of considering and, if thought fit, passing, with or without amendments, the following resolutions.

SPECIAL RESOLUTIONS

1. To consider and approve the Company’s plan for the private issuance of Domestic Unlisted Shares (each and every item as a separate resolution):
 - i. Class and nominal value of the Shares to be issued: Domestic Unlisted Shares, with a nominal value of RMB1.00 per Share.
 - ii. Number of the Shares to be issued: not less than 40,000,000 Domestic Unlisted Shares and not more than 80,000,000 Domestic Unlisted Shares.
 - iii. Target subscribers: not more than 35, the scope of which includes the registered Shareholders of the Company and other eligible investors who comply with the regulations on investor suitability management.
 - iv. Issue price: RMB1.07 per Share, which will be determined by the Board and its authorized persons at the time of the final issuance based on market practices and regulatory requirements, taking into full consideration the interests of Shareholders, investor acceptance and issue risks, as well as the market conditions at that time and the Company’s secondary market share price.

- v. Method of issuance: by way of a non-public issuance of Domestic Unlisted Shares to selected target subscribers, and methods such as public roadshows or book building will not be adopted.
 - vi. Lock-up arrangements: save for the lock-up circumstances stipulated by laws and the Articles of Association, there are no other lock-up arrangements for the Issuance; after the target subscribers are confirmed, all target subscribers shall sign relevant agreements. If there are lock-up arrangements or voluntary lock-up commitments for the new Shares, the specific arrangements shall be subject to the subscription agreements, voluntary lock-up commitments and other documents.
 - vii. Disposal of accumulated undistributed profits: the accumulated undistributed profits prior to the completion of the Issuance shall be shared by all Shareholders of the Company upon the completion of the Issuance in proportion to their respective shareholdings at the relevant time.
 - viii. Use of proceeds: the proceeds from the Issuance will be used to supplement working capital, to optimize the capital structure of the Company, enhance its capital scale, further strengthen its financial strength, improve its profitability and risk resistance, facilitate the Company to better achieve scale expansion and business development, and enhance its overall competitiveness.
 - ix. Place of listing: the Domestic Unlisted Shares in issue and the Domestic Unlisted Shares under the Issuance will be listed on the National Equities Exchange and Quotations, which are also planned to apply for listing on the Beijing Stock Exchange.
 - x. Validity period of the resolution in relation to the Issuance: the resolution in relation to the Issuance shall be valid for 12 months from the date on which the issuance plan of the Issuance is considered and approved at the EGM. If, within the validity period, the Company obtains the consent letter from National Equities Exchange and Quotations Co., Ltd. or the registration approval from the China Securities Regulatory Commission for the Issuance, the validity period shall be automatically extended until the date of completion of the matters relating to the Issuance.
- 2. To consider and approve the Private Issuance Prospectus of AIM Vaccine Co., Ltd. (Revised).
 - 3. To consider and approve Tibet Bohai Subscription Agreement and all the transactions contemplated thereunder and in connection therewith.

4. To consider and approve Mr. Shen Subscription Agreement and all the transactions contemplated thereunder and in connection therewith.

ORDINARY RESOLUTION

5. To consider and approve that the existing Shareholders of the Company shall not be entitled to pre-emptive rights for the Shares under the Issuance.

Details of the above resolutions are set out in the circular dated August 18, 2026 (the “**Circular**”). Unless otherwise indicated, capitalized terms used in this notice shall have the same meanings as those defined in the Circular.

By order of the Board
AIM Vaccine Co., Ltd.
Chairman of the Board and CEO
Mr. Yan ZHOU

Beijing, the PRC, August 18, 2026

Notes:

1. All resolutions at the EGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The results of the poll will be published on the website of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company’s website (www.aimbio.com) after the EGM.
2. Any Shareholder entitled to attend and vote at the EGM convened by the above notice may appoint one or more proxies to attend the meeting and vote instead of him/her while voting by poll. A proxy needs not be a Shareholder of the Company.
3. To be valid, the proxy form together with the power of attorney or other authority, if any, under which it is signed, or a certified copy of such power of attorney or authority, must be completed and returned to the Company’s H Share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, at least 24 hours before the time scheduled for holding the meeting (i.e. before 2:00 p.m. on Sunday, September 6, 2026) or any adjourned meeting thereof (as the case may be). Completion and return of the form of proxy will not preclude the Shareholders of the Company from attending and voting in person at the meeting, and in such event, the instrument appointing a proxy shall be deemed to be revoked.
4. For the purpose of determining the list of H Shareholders who are entitled to attend and vote at the EGM, the register of members of the Company will be closed from Wednesday, September 2, 2026 to Monday, September 7, 2026, both days inclusive, during which period no transfer of Shares will be registered. The record date for determining the identity of the Shareholders who are entitled to attend and vote at the EGM will be Monday, September 7, 2026. In order to be eligible to attend and vote at the EGM, unregistered H Shareholders shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s H Share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, before 4:30 p.m. on Tuesday, September 1, 2026 for transfer registration.

5. In case of joint Shareholders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s). For this purpose, seniority will be determined by the order in which the names stand in the H Share register of members of the Company in respect of the joint shareholding.
6. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.
7. A Shareholder or his/her proxy should produce proof of identity when attending the EGM.
8. The contact details of the above meeting are:

The Office of the Board of AIM Vaccine Co., Ltd.

Address: Room 412, 4/F, Building 6, No. 105 Jinghai 3rd Road, Beijing Economic-Technological Development Area, Beijing, the PRC

Postal code: 100000

Phone: +86 10-8595 0689

Email: aim.securities@aimbio.com

9. All dates and time in this notice refer to Hong Kong dates and time.

As at the date of this notice, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN, Mr. Jie ZHOU and Ms. Ling LIU as executive directors; Mr. Jichen ZHAO as a non-executive director; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Mr. Hui OUYANG and Mr. Weicai SHAO as independent non-executive directors.